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 Abstract  
 
Objective: The objective of this selective EBM review is to determine whether or not CDK 4/6 
inhibitors, in combination with anti-estrogen therapy, improve morbidity and mortality for 
women with advanced breast cancer compared to anti-estrogen monotherapy.  
 
Study Design: Systematic review of three randomized-controlled trials. All three articles were 
published in English between 2015 and 2016.  
 
Data Sources: Two randomized, double-blinded, placebo-controlled trials and one open-label 
randomized controlled trial found using PubMed and NCBI.  
 
Outcomes Measured: Each study assessed morbidity and mortality based on progression-free 
survival or overall clinical benefit (stable disease, partial response, or complete response by 24 
weeks).  
 
Results: All three studies showed significant prolongation of progression-free survival in patients 
that received treatment with anti-estrogen therapy plus an oral CDK 4/6 inhibitor for their 
estrogen receptor-positive, HER2neu negative metastatic breast cancer compared to anti-estrogen 
therapy alone or with placebo. Cristofanilli et al. found that median progression-free survival 
improved from 4.6 months to 9.5 months with combination therapy. Similar results were seen in 
Finn et al. with median progression-free survival of 20.2 months in those receiving combination 
therapy, compared to 10.2 months in women treated with anti-estrogen therapy alone. In the 
study by Hortobagyi et al., the progression-free survival rate at 18 months for those treated with 
CDK4/6 inhibitor was 63%, compared to 42.2% in the placebo group.  
 
Conclusions: These studies suggest that cyclin dependent kinase 4/6 inhibitors used in 
conjunction with anti-estrogen therapy should be considered as an efficacious treatment regimen 
for postmenopausal patients with hormone receptor-positive, HER2neu negative advanced breast 
cancer. Finn and Hortobagyi, and colleagues, investigated the use of an aromatase inhibitor, 
letrozole, for anti-estrogen therapy. Cristofanilli and colleagues studied the efficacy of an 
estrogen receptor downregulator, fulvestrant. Additionally, palbociclib was used for inhibition of 
the CDK4/6 pathway in two studies, while ribociclib was used in the other. Improvement in 
progression-free survival and overall response was seen in all three studies regardless of the 
combination of drugs being used. 
 
Key Words: Cyclic dependent kinase, palbociclib, fulvestrant, advanced breast cancer 
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INTRODUCTION 
 
 Breast cancer is characterized by the formation and growth of malignant cells within 
breast tissue. It is the most commonly diagnosed cancer in women, and the second leading cause 
of cancer death in this group.1 Approximately 3.5 million women in the US are living with breast 
cancer; it is estimated that another 252,710 new cases will be diagnosed in 2017.1 In 2010, the 
estimated cost of treating breast cancer in the US was ~$16.5 billion, and that number is 
expected to increase to $20.5 billion by 2020.2 
Breast cancer can be classified as in situ (confined to its site of origin) or invasive 
disease, and has multiple molecular subtypes. Age is the most common risk factor for breast 
cancer, with the majority of diagnoses made after age 50. Additional risk factors include genetic 
tendency, positive family history of breast or ovarian cancer, having dense breasts or prior 
benign breast disease, sedentary lifestyle, diet high in saturated fat, excess alcohol consumption, 
and the use of HRT.1 Additionally, due to extended exposure to hormones, women who have 
early menarche or late menopause are at an increased risk for developing breast cancer.  
 Mammography has become a useful tool in detecting breast cancer. The American 
Cancer Society recommends that women ages 40 to 44 have the choice to start yearly screening 
mammograms, and those women 45 and older should be screened annually.3 At age 55, annual 
screenings can continue, or a woman can choose to have the exam performed every two years 
instead.3 It is recommended that screening start sooner for high-risk individuals (e.g. strong 
family history, known genetic mutation). Breast cancer can be asymptomatic, with the first sign 
of disease being an abnormality seen on imaging studies. Those with symptomatic disease might 
notice a palpable breast mass, change in breast contour or the overlying skin, or nipple discharge. 
Additionally, patients with malignancy may complain of fatigue. Symptoms of advanced breast 
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cancer are commonly associated with disease location; breast cancer most commonly 
metastasizes to regional lymph nodes, bones, lung, liver and brain. An individual may 
subsequently experience lymphadenopathy, bone/back pain, nausea and vomiting, anorexia, 
weight loss, dry cough, shortness of breath, or changes in mentation.  
Treatment of breast cancer is a multi-factorial approach and can include breast surgery 
with lumpectomy or mastectomy, axillary biopsy and resection, radiation to local or metastatic 
disease, systemic chemotherapy, and endocrine therapy. Patients with bony disease might also 
benefit from bisphosphonate derivatives. When considering clinical treatment, three genetic 
distinctions are considered: 1) estrogen receptor status 2) progesterone receptor status, and 3) 
HER2neu gene overexpression.4 Of those diagnosed with invasive disease, ~71% are hormone 
receptor-positive, HER2neu negative.1 Roughly 5% of women have stage 4 disease at the time of 
diagnosis, and the estimated 5-year survival for those with distant metastatic disease is 26%.5 For 
these patients, hormonally directed therapy remains the mainstay of treatment, but is seldom 
effective as these patients can quickly develop endocrine resistance.4,6,7 Managing these resistant 
cases continues to be a challenge within the medical community. Alteration in the cell cycle is a 
well-known characteristic in the development and spread of cancer. Multiple studies have 
investigated the role of various signaling pathways and receptor mutations that contribute to such 
cases. Cyclin dependent kinases (CDK) are a group of kinases that work together with regulatory 
proteins to control progression through the cell cycle; alteration and activation of the CDK 4/6 
axis has been found to be a common feature in hormone receptor-positive cancer.4 Studies have 
found that inhibiting this pathway is associated with arresting sensitive human breast cancer cells 
in the G1 phase of their cell cycles, with the effect being especially potent in receptor-positive 
breast cancers.4 This paper evaluates three randomized controlled trials comparing the efficacy 
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of combination therapy with cyclin dependent kinase 4/6 inhibitors and anti-estrogen 
medications at improving progression-free survival in patients with advanced disease.  
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not CDK 4/6 
inhibitors, in combination with anti-estrogen therapy, improve morbidity and mortality for 
women with advanced breast cancer compared to anti-estrogen monotherapy. 
METHODS 
 
The author of this selective review searched articles using PubMed and NCBI. Key words 
in the search included cyclin dependent kinase, palbociclib, fulvestrant, and advanced breast 
cancer. Articles were considered if they were relevant to the clinical question and included 
POEMs, were written in English, and had been published within the last 10 years. Exclusion 
criteria included previous Cochrane reviews, as well as previous selective EBM reviews 
submitted by prior students. This research study analyzed three RCTs. The population in all three 
studies included women over age 18 who had estrogen receptor-positive, HER2neu negative 
advanced breast cancer. Two of the three studies, conducted by Finn et al. and Hortobagyi et al., 
evaluated a CDK 4/6 inhibitor plus anti-estrogen therapy as a first-line systemic treatment for 
advanced disease, while the other, performed by Cristofanilli and colleagues, included patients 
who had metastatic breast cancer that progressed on previous endocrine therapy. Palbociclib or 
ribociclib were representative of CDK4/6 inhibitors, while letrozole or fulvestrant were used for 
anti-estrogen therapy.  Efficacy analysis was performed on the intention-to-treat population and 
the studies reported numbers needed to treat (NNT), p-values, and confidence intervals (CI). 
Table 1 shows the demographics and characteristic of the included studies.  
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The first study by Cristofanilli et al. evaluated 521 women with any menopausal status 
that had disease progression on previous anti-estrogen therapy. Women who had received a 
previous CDK inhibitor, fulvestrant, everolimus or a P13K/mTOR pathway inhibitor were 
excluded. The women were randomly assigned to receive palbociclib plus fulvestrant or placebo 
plus fulvestrant. Oral palbociclib 125 mg or placebo were administered once daily for three 
weeks followed by one week off, on a 28-day cycle. Fulvestrant was given to each groups on the 
following schedule: 500 mg IM injection day 1 and day 15 of cycle 1, then day 1 of each 
subsequent 28-day cycle. All premenopausal or perimenopausal women had to have started 
treatment with a luteinizing-hormone-releasing-hormone agonist, goserelin, at least four weeks 
before randomization. Additionally, during the treatment period, those women received goserelin 
at the time of fulvestrant administration.  
The second RCT by Hortobagyi et al. included 668 postmenopausal women with 
recurrent or metastatic breast cancer who had not received prior systemic therapy for their 
advanced disease. Measurable disease by Response Evaluation Criteria in Solid Tumors 
(RECIST) had to be present or the patients had to have at least one predominately lytic bony 
lesion. Additional inclusion criteria included an Eastern Cooperative Oncology Group 
Performance Status of 0 or 1. Patients with inflammatory breast cancer or central nervous system 
metastasis were excluded. Women were randomly assigned to receive either oral ribociclib plus 
letrozole or letrozole plus placebo on the following regimens: 1) oral ribociclib 600 mg daily for 
three weeks, followed by one week off, on a 28-day cycle plus oral letrozole 2.5 mg daily, or 2) 
oral letrozole 2.5 mg daily plus placebo, and a schedule similar to those receiving ribociclib.  
The final RCT by Finn et al. included 165 post-menopausal women who were selected to 
participate if they had locally recurrent disease not amenable to surgery or evidence of metastatic 
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disease; those with brain metastasis were excluded. The women were randomly assigned to 
receive either palbociclib plus letrozole or letrozole alone. The following treatment regimens 
were followed: 1) oral palbociclib 125 mg, given once daily for three weeks followed by one 
week off, on a 28-day cycle plus oral letrozole 2.5 mg daily or 2) oral letrozole 2.5 mg daily. 
Table 1. Demographics and characteristics of included studies 
Study Type # pts Age  Inclusion Criteria Exclusion Criteria W/D Interventions 
Cristofanilli6 
(2016) 
RCT 521  >18 
yo 
Menopausal 
(natural or 
medically 
induced), ECOG 
0-1, measurable 
disease or bone 
disease only, 
relapse/progression 
after previous 
endocrine therapy 
during tx or within 
12 months, one 
line of 
chemotherapy in 
advanced disease 
was allowed  
Received CDK 
inhibitor, 
fulvestrant, 
everolimus, 
P13K/mTO 
inhibitor; 
extensive 
symptomatic 
visceral mets; 
uncontrolled CNS 
mets 
275* Fulvestrant 
500 mg IM 
(day 1 & 15 
of cycle 1; 
then day 1 of 
28-day cycle) 
plus oral 
palbociclib 
125 mg (3 out 
of 4 weeks) 
vs. fulvestrant 
IM plus 
placebo 
Finn4 (2015) RCT 165 >18 
yo 
Post-menopausal, 
ER+ advanced 
disease, locally 
recurrent tumor not 
amenable to 
surgery,  
metastatic disease, 
measurable tumor 
by RECIST, 
adequate organ 
function  
Received 
letrozole within 
12 months, 
previous systemic 
treatment for 
advanced disease, 
brain mets, 
previous CDK 
inhibitor 
133* Daily oral  
letrozole 2.5 
mg plus oral 
palbociclib 
125 mg (3 out 
of 4 weeks) 
VS. daily oral 
letrozole 
Hortobagyi7  
(2016) 
RCT 668 >18 
yo 
Post-menopausal, 
locally HR+ 
recurrent or 
metastatic disease, 
measurable disease 
per RECIST, one 
predominant lytic 
bone lesion 
Inflammatory 
disease, CNS 
mets, previous 
CDK inhibitor, 
previous systemic 
tx for advanced 
disease 
319* Ribociclib 
600 mg (3 out 
of 4 weeks) 
plus letrozole 
2.5 mg daily  
VS. placebo 
plus letrozole  
*W/D due to objective progression or relapse, adverse events, withdrawal of consent, protocol, patient or physician 
decision, global deterioration of health status, or death 
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OUTCOMES MEASURED 
 
All three studies primarily assessed morbidity and mortality based on progression-free 
survival according to RECIST. This criterion defines when tumors in cancer patients improve, 
stay the same, or worsen during the treatment course.  
In the study by Cristofanilli et al., study treatment continued until disease progression, 
unacceptable toxic effects, withdrawal of consent, or death. Tumors were assessed at baseline by 
CT, MRI, or both, as well as every 8 weeks (+/- 7 days) for the first year and every 12 weeks 
thereafter. Patients with only bone lesions had follow-up CT or MRI every 8 weeks during active 
treatment for the first year, followed by every 12 weeks from the date of randomization. 
Confirmation of complete response was also performed. To measure progression-free survival, 
an audit approach with random sample-based, masked, independent central review was used.6 In 
the study by Finn et al., tumor assessments were done by CT or MRI of chest, abdomen, and 
pelvis at screening and every 8 weeks thereafter. Bone scans were performed, if applicable, at 
baseline and then every 12 weeks. Progression-free survival was defined as time to radiological 
disease progression from randomization or death on the study.4 Hortobagyi et al. assessed tumor 
response by CT or MRI at screening, every 8 weeks during the first 18 months, and every 12 
weeks thereafter until disease progression, as well as at the end of treatment. An independent 
review committee whose members were unaware of treatment assignments prospectively 
reviewed all imaging data.7  
RESULTS  
The three RCTs evaluated in this selective review assessed the role of CDK4/6 inhibitors 
in the treatment of advanced breast cancer. Cristofanilli et al. conducted a multicenter, double-
blind RCT that randomly assigned 521 women that progressed on previous endocrine therapy to 
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either receive fulvestrant plus palbociclib (n=347) or fulvestrant plus placebo (n=174). 
Administration schedule discussed in detail above. Assignments were made between October 7, 
2013 and August 26, 2014 and overall survival follow-up is ongoing. By March 16, 2015, 259 
progression-free survival events had occurred, 145 in the palbociclib group and 114 in the 
placebo group.6 In the palbociclib group, median progression-free survival was 9.5 months (95% 
CI 9.2-11.0), compared to 4.6 months (95% CI 3.5-5.6) in the control group.6 Best overall tumor 
response for all participants was also assessed, and is described in Table 2 below. Clinical 
benefit, defined as complete response plus partial response plus stable disease > 24 weeks, was 
evaluated in both groups.6 Of the 347 subjects in the treatment group, 231 were identified as 
having clinical benefit, while 69 out of the 174 participants in the control group had the same 
classification.6 Absolute benefit increase for this study was 27% and numbers needed to treat 
(NNT) equated to 4, with p-value statistically significant at <0.0001. Safety assessment included 
patients who received at least one dose of study drug. The most common side effect in the 
palbociclib group was neutropenia of any grade, occurring substantially more frequently than in 
the control group at 81% and 3%, respectively.6 Additionally, infection, fatigue, nausea, other 
blood dyscrasias, rash, and alopecia were more common in the palbociclib group. Serious 
adverse effects accounted for a dose interruption in 54% of the treatment group versus 6% in the 
placebo group.6 No deaths related to treatment toxicity occurred in either group. All subjects 
were accounted for at the conclusion of the trial.  
Table 2. Efficacy of Combination Therapy as Measured by Cristofanilli et al. 2016 
 Fulvestrant plus palbociclib Fulvestrant plus placebo 
Clinical benefit* 67% 40% 
95% Confidence Interval  61.3-71.5 32.3-47.3 
Treatment effect 
CER EER RBI ABI NNT p-value 
0.40 0.67 0.675 0.27 4 <0.0001 
*Clinical benefit in the intention-to-treat population is defined by complete response plus partial response plus stable 
disease equal to or more than 24 weeks 
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Between December 22, 2009 and May 12, 2012, Finn et al. randomly assigned 165 
women to receive palbociclib plus letrozole (n=84) or letrozole alone (n=81). At the time of final 
analysis, 41 progression-free events occurred in the treatment group, versus 59 in the control 
group.4 Median progression-free survival was 20.2 months (95% CI 13.8-27.5) and 10.2 months 
(95% CI 5.7-12.6), respectively.4 Of note, a greater proportion of patients had an objective 
response to treatment and achieved clinical benefit in the palbociclib plus letrozole group 
compared to those receiving only letrozole.4 This study also assessed overall survival at the time 
of the final progression-free survival interval. In the palbociclib group, median overall survival 
was 37.5 months (95% CI 28.4-NE) and 33.3 months (26.4-NE) in the letrozole group (HR 
0.813, 95% CI 0.492-1.345; two-sided p=0.42).4 Similar to the other two studies, the most 
common adverse effect in those receiving palbociclib was neutropenia. All patients who received 
palbociclib plus letrozole had an adverse event, including leukopenia and fatigue, compared to 
84% of patients who received letrozole alone; dose interruptions were required for 33% of the 
combination group, compared to only 4% of the letrozole group.4 Despite the increase in adverse 
events in the treatment group, this accounted for only 13% of discontinuation from the study, 
versus 2% in the control group.4 Most discontinuations were secondary to progression of disease 
and were more common in the patients receiving monotherapy, accounting for 70% of patients in 
that group, versus 50% of patients on combination therapy.4 
Table 3. Progression-free Survival with Combination Therapy vs Anti-estrogen 
Monotherapy as Measured by Finn et al. 2016 
 Palbociclib plus letrozole Letrozole alone 
Median progression-free survival 20.2 months 10.2 months 
95% Confidence Interval  13.8-27.5 5.7-12.6 
Treatment effect 
Hazard ratio 0.488 
95% Confidence interval 0.319-0.748 
One sided p-value 0.0004 
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In the trial by Hortobagyi and colleagues, from January 24, 2014 to March 24, 2015, 668 
post-menopausal women were randomly assigned to receive ribociclib plus letrozole (n=334) or 
placebo plus letrozole (n=334) for first-line treatment of their recurrent or metastatic breast 
cancer. Treatment regimens are noted above. By January 29, 2016, 349 patients were still 
receiving treatment, 195 in the ribociclib group and 154 in the placebo group.7 Of those that 
discontinued treatment, progressive disease accounted for the reason in 26% of the ribociclib 
group, versus 154 in the control group. For this study, a pre-specified interim analysis was 
conducted when at least 211 patients progressed or died. It should be noted that the median 
duration of progression-free survival was not reached in the ribociclib group, but was 14.7 
months in the placebo group. After 18 months, however, progression-free survival was 63% 
(95% CI 54.6-70.3) and 42.2% (34.8-49.5), respectively.7 These results were supported by 
blinded central analysis. With the end-point of progression-free survival at 18 months, ABI is 
20.8% with NNT=5. Similar to the study conducted by Cristofanilli discussed above, safety 
analyses were evaluated in those patients that received at least one dose of a study regimen; 
patients were also required to have at least one safety assessment after baseline. Dose 
adjustments were permitted to manage treatment-related adverse reactions secondary to 
ribociclib but not for letrozole. Neutropenia was the adverse event leading to the most dose 
reductions in the ribociclib group (n=104). This effect was not observed in patients receiving 
placebo. 
Table 4. Efficacy of Ribociclib Plus Letrozole as Measured by Hortobagyi et al. 2016 
 Ribociclib group Placebo group 
Progression-free survival at 18 
months 
63% 42.2% 
95% Confidence Interval  54.6-70.3% 34.8-49.5% 
Treatment effect 
CER EER RBI ABI NNT 
0.422 0.62 0.493 0.208 5 
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DISCUSSION 
 
 As previously discussed, breast cancer is a common malignancy effecting over 3 million 
women in the United States. Treatment regimens for those with advanced disease are limited, 
with no known cure available at this time. While endocrine therapy, surgery, radiation, and 
chemotherapy offer some improvement in survival, drugs that target specific signaling pathways 
must be considered as an alternative treatment option in patients at advanced stages of 
malignancy. The study by Cristofanilli et al. showed an improvement in progression-free 
survival, objective response, and clinical benefit in participants that received fulvestrant plus 
palbociclib. This study evaluated the use of combination therapy in patients who failed previous 
treatment, and the benefit was observed regardless of home many prior endocrine therapies they 
had tried. Additionally, the level of expression of estrogen and progesterone receptors did not 
significantly alter the above results.6 Hortobagyi’s and Finn’s analyses also showed the addition 
of ribociclib or palbociclib to letrozole improved time until progression when initiated as first-
line management for advanced breast cancer. Finn’s research also demonstrated clinically 
significant benefit with combination therapy despite the patient’s menopausal status prior to 
receiving treatment. A limitation to all studies was that dose reductions were necessary in a 
higher proportion of the treatment group. Although the use of these novel agents is associated 
with an increased risk of myelosuppression, the adverse events were manageable, and did not 
appear to have a significant effect on the primary end-point for the studies. The above data 
suggest that there is an important clinical role for the use of cyclin dependent kinase inhibitors in 
the management of breast cancer.  
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CONCLUSIONS  
This systematic review showed that the use of CDK4/6 inhibitors in combination with 
anti-estrogen therapy improves progression-free survival in women with hormone receptor-
positive, HER2neu negative advanced breast cancer compared to anti-estrogen therapy alone. 
Clinical benefit was seen in all three studies irrespective of the choice of combination therapy 
used. Finn and Hortobagyi described the role of CDK 4/6 inhibition plus anti-estrogen as a first-
line treatment option, while Cristofanilli found the combination regimen to also be effective in 
those who had progressed on previous endocrine therapies. For future studies regarding the use 
of CDK 4/6 inhibitors, it would be beneficial to have a better understanding of the long-term 
effects of prolonged use, specifically related to myelosuppression and bone marrow toxicity.  
Finn addressed the question regarding efficacy in premenopausal as well as postmenopausal 
women. This inclusion criterion could extend to future studies to increase generalizability of the 
patient population.  
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